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Abstract
Vascular endothelial growth factor (VEGF) is being investigated as a potential interventional therapy for spinal
cord injury (SCI). In the current study, we examined SCI-induced changes in VEGF protein levels using Western
blot analysis around the epicenter of injury. Our results indicate a significant decrease in the levels of VEGF165
and other VEGF isoforms at the lesion epicenter 1 day after injury, which was maintained up to 1 month after
injury. We also examined if robust VEGF165 decrease in injured spinal cords affects neuronal survival, given that
a number of reported studies show neuroprotective effect of this VEGF isoform. However, exogenously ad-
ministered VEGF165 at the time of injury did not affect the number of sparred neurons. In contrast, exogenous
administration of VEGF antibody that inhibits actions of not only VEGF165 but also of several other VEGF
isoforms, significantly decreased number of sparred neurons after SCI. Together these results indicate a general
reduction of VEGF isoforms following SCI and that isoforms other than VEGF165 (e.g., VEGF121 and=or VEGF189)
provide neuroprotection, suggesting that VEGF165 isoform is likely involved in other pathophysiological process
after SCI.
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Introduction
Vascular endothelial growth factor (VEGF) is apotent stimulator of angiogenesis and a mediator of
vascular permeability (Connolly et al., 1989; Ferrara et al.,
2003; Leung et al., 1989; Senger et al., 1983). In addition to the
angiogenic and vascular permeability properties, VEGF is
also considered to have neuroprotective effects (Facchiano
et al., 2002; Oosthuyse et al., 2001; Svensson et al., 2002) and
thus may be a critical mediator in the recovery after spinal
cord injury (SCI).
The VEGF family consists of six different members:
VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, and placental
growth factor (PlGF) (Ferrara et al., 2003). The most pre-
dominant form is VEGF-A, which is alternatively spliced into
six different isoforms identified as 121, 145, 165, 183, 189, and
206 (Robinson and Stringer, 2001). VEGF165 is the most pre-
dominant of the six different isoforms and is found both dif-
fusible, and bound to the cell surface and extracellular matrix
(Park et al., 1993). VEGF isoforms 121 and 145 are freely dif-
fusible, while 183 and 189 are strongly bound to the extra-
cellular matrix (Ferrara et al., 2003; Jingjing et al., 1999;
Poltorak et al., 1997; Zachary, 2001). Most biological effects of
VEGF are mediated via two receptor tyrosine kinases,
VEGFR1 (KDR=Flk-1) and VEGFR2 (Flt-1) (Ferrara et al.,
2003; Neufeld et al., 1999; Zachary, 2003), but specific VEGF
isoforms also bind neuropilins 1 and 2, non-tyrosine kinase
receptors originally identified as receptors for semaphorins,
polypeptides with essential roles in neuronal patterning
(Gluzman-Poltorak et al., 2000; Makinen et al., 1999; Migdal
et al., 1998; Soker et al., 1998).
Recent studies have examined the effect of acute adminis-
tration of VEGF in SCI, albeit with different outcomes (Benton
and Whittemore, 2003; Widenfalk et al., 2003). Studies by
Widenfalk et al. (2003) indicated that acute administration of
VEGF improved behavioral outcome and reduced the lesion
volume and level of apoptosis following SCI (Widenfalk et al.,
2003), while the study by Benton and Wittenmore (2003) in-
dicated that acute VEGF administration exacerbated lesion
volume resulting in poor functional recovery (Benton and
Whittemore, 2003). To date, the use of VEGF treatment fol-
lowing SCI is controversial. Additionally, the expression and
role of VEGF in injured spinal cord are not well understood.
Therefore, the major focus of our study was to examine the
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expression profile of VEGF165 following SCI. We examined
the protein levels of VEGF165 via Western analysis and ob-
served a significant decrease at the lesion site 1 day after in-
jury that persisted up to 1 month post-injury. Additionally,
we determined that suppressing VEGF expression by acute
administration of a neutralizing antibody reduced the num-
ber of neuronal cells around the lesion at chronic time points.
Methods
Animal subjects and surgery
All surgical procedures and subsequent care and treatment
of all animals used in this study were in strict accordance with
NIH guidelines for animal care. Our institutional animal
welfare committee approved these studies.
To examine the VEGF protein expression profile at 1, 7, 14,
and 28 days post-injury, a total of 18 male Sprague-Dawley
rats (300–350 g)were used and compared to six sham controls.
SCIs were performed as described previously (Ramu et al.,
2007; Scheff et al., 2003). Briefly, animals were anesthetized
with 4% isoflurane, and maintained under anesthesia with a
mixture 2% isoflurane, air, and oxygen, administered through
a Harvard rodent ventilator (model 683; Harvard Apparatus,
South Natic, MA) during the entire procedure. A lami-
nectomy was performed at the 7th thoracic vertebra (T7), and
the T6 and T8 vertebral process were clamped to stabilize the
vertebral column. A 150-kDyne force was delivered to the
exposed cord to produce a moderate level of injury using an
Infinite Horizon Impactor (Precision System and In-
strumentation, Lexington, KY). The animals were allowed to
recover in warmed cages and received subcutaneous injec-
tions of Baytril-100 (2.5mg=kg, Bayer Healthcare LLCAnimal
Division, Shawnee Mission, KS) twice a day for 3–5 days, and
Buprenex (0.01mg=kg, Hospira, Inc., Lake Forest, IL) twice a
day for 5 days. Animals were also administered subcutaneous
injections of saline twice daily for 5 days. The animals’ blad-
ders were manually expressed twice daily by the method of
Crede until the return of spontaneous urination. Animals had
free access to food and water.
VEGF165 exogenous administration
To examine the neuroprotective role of VEGF, a total of 32
adult male Sprague-Dawley rats (300–350 g) were used. Rats
were divided into four different groups (n¼ 8=group).
Groups 1–3 received a single injection (1.5 ml) of either saline,
human recombinant VEGF165 (4mg=ml; catalog no. 293-VE,
R&D Systems; Minneapolis, MN), or anti-VEGF (4 mg=ml;
catalog no. AF564, R&D Systems), respectively, immediately
after injury. The bioactivity of both the protein and antibody
were tested, and specific details are provided by R&D Sys-
tems. Sham controls receiving only a laminectomy served as
Group 4. Injections were delivered at a depth of 1.2mmbelow
the surface directly into the contusion site at a rate of
0.5 ml=min through a glass pulled needle driven by a picos-
pritzer (Parker Hannifin Corporation, Fairfield, NJ). We used
the same concentration of VEGF that was employed in a
previous study (Widenfalk et al., 2003). Animals were sacri-
ficed after 56 days for the neuroprotection analysis. Analysis
of the behavioral data, histology, and magnetic resonance
imaging (MRI) analysis from the above groups is in progress
and will be reported in a subsequent manuscript.
Tissue processing for Western analysis
ForWestern analysis, animals were transcardially perfused
with saline, and the endogenous expression of VEGF was
determined at days 1, 7, 14, and 28 after injury. Spinal seg-
ments were processed for Western analysis as described
previously (Nesic et al., 2006) with a fewminor modifications.
Briefly, the lesion site consisting of a 2–3-mm spinal segment
was removed and homogenized in a solution of T-PER
(Tissue Protein Extraction Reagent; Pierce, Rockford, IL)
supplemented with Complete, EDTA-free protease inhibitor
cocktail (Roche, Indianapolis, IN). The buffer and sample mix
were homogenized at 48C using a hand-held glass homoge-
nizing pestle. After the homogenization, all samples were
centrifuged at 48C for 10min at 10,000 rpm. Supernatant
samples were frozen and stored at 208C. All samples were
processed on the same day to avoid any changes in sample
preparations.
Western analysis
Western analysis was performed on all samples as de-
scribed previously with a few minor modifications (Nesic
et al., 2006). Briefly, the amount of protein in each sample was
measured using the Bradford assay employing bovine serum
albumin (BSA) as a standard. Equal amounts of protein
(40 mg) were then boiled for 10min with appropriate volume
of 6sample buffer (350 nMTris-HCL, pH 6.8, 1MUrea, 1% 2-
mercaptoethanol, 9.3% DTT, 13% sodium dodecyl sulfate
[SDS], 0.06% bromophenol blue, and 30% glycerol). Samples
were then resolved on a 12% SDS–polyacrylamide gel and
separated at 150 v for 4 h. The gel was then transferred over-
night to a polyvinyl difluoride (PVDF) membrane at 48C. The
membrane was then reversibly stained with Ponceau S to
confirm transfer of proteins and then destained in distilled
water. The membranes were blocked for 1 h at room tem-
perature in 5% BSA in Tris-buffered saline with Tween-20
(TBST; 10mM Tris-HCl, pH 7.9, 150mM NaCl, and 0.05%
Tween-20). The following primary antibodies were used:
rabbit anti-VEGF (sc-507, 1:300; Santa Cruz Biotechnology,
Santa Cruz, CA) and mouse anti-Beta actin (1:80,000; Sigma-
Aldrich, St. Louis, MO) was used as a loading control. Both
primary and secondary antibodies were diluted in blocking
solution, and washed with Tris-buffered saline containing
0.2% Tween-20. Peroxidase activity was detected using the
Amersham enhanced chemiluminescence system (ECL;
RPN2209, Amersham Biosciences, Piscataway, NJ).
Preincubation of anti-VEGF with SCI sample
The expression of the VEGF165 isoform was confirmed by
performing a preincubation of the 24-h sample with a re-
combinant human VEGF165 (catalog no. 293-VE; R&D Sys-
tem), with a volume ratio of 1:10, respectively. The control
peptide was reconstituted as recommended by the manufac-
turer. The antibody=sample solution was left for overnight
mixing at 48C. The samples were then boiled and processed
for Western analysis as described above.
Immunohistochemistry and image acquisition
Animals receiving acute spinal injections after injury were
perfused with saline followed by 4% paraformaldehyde in
phosphate-buffered saline (0.1M PBS) at 56 days post-injury.
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The spinal cords were removed, post-fixed overnight in 4%
paraformaldehyde, and then immersed in 30% sucrose=0.1M
PBS for 2–3 days at 48C. The spinal cord was divided into
epicenter, rostral, and caudal segments. Each segment was
3mm in length. Segments were then sectioned coronally at a
thickness of 40 mm using a cryostat (model CM1800; Leica,
Bannockburn, IL), and sectionswere stored at208C in tissue-
storing media.
Spinal cord sections were processed as free floating and
were incubated in the following antibodies: neuronal nuclei
(NeuN; Millipore, Billerica, MA), glial fibrillary acidic protein
(GFAP; Millipore), and VEGF (Santa Cruz Biotech). The pri-
mary antibody was diluted with blocking solution (0.1M PBS
containing 5% goat serum and 0.3% Triton X-100). For con-
trols, only secondary antibodies were applied to determine
the antibody specificity.
Appropriate secondary antibody was used at a dilution of
1:500 in 0.1M PBS containing 5% goat serum and 0.3% Triton
X-100. The following Alexafluor dye conjugated secondary
antibodies were used: goat anti-mouse IgG Alexa Fluor 488
(Invitrogen, Carlsbad, CA) and goat anti-rabbit IgG (HþL)
Alex Fluor 568 (Invitrogen). Tissue sections for NeuNþ
nuclei quantification and co-labeling with VEGFwere viewed
and captured using a Spot Flex digital camera (Diagnostic
Instruments, Inc., Sterling Heights, MI) attached to a Leica
RX1500 upright microscope, and the images were collected
using the Spot software. Operator acquiring the images was
blinded to the groups.
Neuroprotection analysis
Spinal cord sections (n¼ 10 sections=animal) were ana-
lyzed from both rostral and caudal segments of all animals
(n¼ 8 animals=group). The epicenter segment was not ana-
lyzed due to the large amount of tissue damage. The numbers
of NeuNþ neuronal nuclei were quantified in the entire cor-
onal section using ImagePro Plus software (Media Cyber-
netics, Inc., Silver Spring, MD). Threshold levels were
FIG. 1. Western analysis examining the expression of vascular endothelial growth factor (VEGF) at the lesion epicenter 1 day
after spinal cord injury (SCI). VEGF was reduced in SCI samples compared to sham controls. Multiple bands may indicate the
multiple VEGF isoforms in spinal cord tissue.
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determined from intact spinal cord sections and secondary
control sections. These levels were applied to other groups.
The nuclei were quantified in ImagePro and verified by
manually counting neuronal nuclei. Operator quantifying cell
nuclei was blinded to the groups.
Statistical analysis
Statistical analysis for Western and neuroprotection
study was performed using a one-way analysis of variance
(ANOVA) followed by Tukey’s multiple range test, and dif-
ferences were considered significant if p< 0.05. Statistical
analysis was performed using GraphPad Prism4 software
(GraphPad Software, San Diego, CA).
Results
Quantitative assessments of VEGF protein level changes
over time after SCI were based on Western blot analaysis and
a polyclonal antibody that recognizes three VEGF isoforms:
121, 165, and 189. As mentioned earlier, VEGF isoform 121 is
freely diffusible, 165 is both bound to matrix and freely dif-
fusible, and 189 is strongly bound to the extracellular matrix
(Ferrara et al., 2003). As shown previously, all three VEGF
isoforms are expressed in the rat spinal cords, similar to hu-
man spinal cords (Ferrara et al., 2003).
As shown in Figure 1, representative VEGF Western blot
indicates several bands (27–100 kD), which likely correspond
to different VEGF isoforms expressed in spinal cord tissue. All
VEGF-bands were reduced in injured spinal cords at 1 day
post-SCI (n¼ 3), suggesting that SCI induced decrease in the
expression levels of all three VEGF isoforms.
Since VEGF isoform 165 is most often studied in SCIs
(Benton and Whittemore, 2003; Widenfalk et al., 2003), we
identified the band in the Western blot that was 165-specific,
using a standard competition experiment shown in Figure 2A
(n¼ 2). We preincubated VEGF antibody with rat VEGF165
peptide (1:10), and after subsequent Western blotting, the
27-kD band was significantly reduced, in contrast to other
bands with higher molecular weight, which may represent
SDS-resistant multimers of other VEGF isoforms or are non-
specific bands. Furthermore, we also loaded or ‘‘spiked’’ pu-
rified rat VEGF165 at two different concentrations (0.2 and
0.02mg) and found that a band of 25 kD (Fig. 2B) that closely
corresponds to the strongest band of 27 kD in the spinal cord
samples. Discrepancy between those two molecular bands
likely indicates glycosylation of VEGF165 in spinal cord tissue
(Brandner et al., 2006).
Based on these results, the 27-kD band appears to be
VEGF165 specific. We have, therefore, performed quantitative
analyses of 27-kD bands in sham and SCI samples at different
post-SCI time points at 2–3-mm segments surrounding site of
injury. As shown in Figure 3, SCI induced a significant de-
crease in VEGF165 levels as early as 1 day ( p< 0.05; n¼ 5) that
persisted for 1 month after SCI ( p< 0.05; n¼ 5), in both rostral
and caudal regions.
VEGF expression was observed in both gray and white
matter in normal spinal cord (Fig. 4). Neuronal cell bodies in
the gray matter were identified by NeuN labeling (Fig. 4B)
FIG. 2. One-day post–spinal cord injury (SCI) samples preincubated with vascular endothelial growth factor (VEGF)
antibody. (A) Western analysis of 24-h samples indicating a reduction in the VEGF165 isoform. (B) A Western blot of
VEGF165 samples at 2 and 0.02mg=ml concentration in each lane, respectively, preincubated with an anti-VEGF antibody.
VEGF165 isoform was reduced in the preincubated Western blot.
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and were observed co-labeling with VEGF (Fig. 4C). Astro-
cytic populations observed in the white matter determined by
GFAP labeling (Fig. 4E) also demonstrated co-labeling with
VEGF (Fig. 4F) in uninjured cord. Normal spinal cord sections
indicate a clearly defined gray and white matter regions with
the most predominant VEGF labeling in the gray matter (Fig.
5A). The uninjured spinal cord displayed typical GFAP la-
beling (Fig. 5B). However, when examining GFAP labeling in
an injured section taken from around the lesion epicenter,
there appears a typical upregulation of GFAP (Fig. 5D). VEGF
expression was also observed (Fig. 5C), but there was a sig-
nificant loss of tissue and disruption of tissue intergrity in the
lesion epicenter.
We hypothesized, based on the VEGF expression levels
observed from theWestern analysis and histologic staining of
injured spinal cord, that supplementing the injured environ-
ment with VEGF165 may increase potential neuroprotective
effects of VEGF as observed in other studies (Choi et al., 2007;
Facchiano et al., 2002; Oosthuyse et al., 2001; Svensson et al.,
2002; Widenfalk et al., 2003). We therefore exogenously de-
livered 1.5 ml of 4mg=ml VEGF165 via direct injection over
5min into the lesion site at the time of injury as described
previously by Widenfalk et al. (2003). As shown in Figure 6,
exogenous administration of VEGF165 did not affect the
number of neurons, quantified using the neuronal nuclei
specific marker NeuN.
FIG. 3. Temporal vascular endothelial growth factor
(VEGF) expression profile in regions around the lesion epi-
center after spinal cord injury (SCI) compared to sham con-
trols. VEGF165 isoform was significantly reduced 1 day after
injury and remained reduced out to 28 days post-injury.
Error bars represent standard error of the mean. Significance
levels were set at p> 0.05.
FIG. 4. Immunofluoresence labeling of neurons and astrocytes expressing vascular endothelial growth factor (VEGF) in
uninjured spinal cord. VEGF expression (A) was observed in neuronal cell bodies in the ventral gray matter identified by
NeuN labeling (B). Neurons double labeled for neuronal nuclei (NeuN) and VEGF are identified by arrowheads (C). VEGF
expression (D) was also observed in astrocytic cells labeled with glial fibrillary acidic protein (GFAP) (E) in the lateral white
matter. (F) Represents astrocytic process double labeled with GFAP identified with arrowheads. Scale bar¼ 100 mm.
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Interestingly, the delivery of anti-VEGF antibody (direct
injection of 1.5 ml at a 4mg=ml concentration) caused a sig-
nificant decrease in the number of NeuNþ cells in injured
animals compared with VEGF, saline, or controls (Fig. 6). This
VEGF antibody identified the same isoforms as the antibody
used in Western blot experiments (Fig. 1). This ensured that
the same VEGF isoforms whose protein levels were reduced
after SCI (likely VEGF121 and VEGF189) are also the ones
whose actions were blocked with VEGF antibody adminis-
tration. This result suggests that VEGF isoforms other than
VEGF165 (such as VEGF121 or VEGF189) may have a role in
sparing neurons after SCI.
Discussion
Decreased VEGF protein levels after SCI
To the best of our knowledge, VEGF protein levels fol-
lowing contusive SCI have not been previously analyzed,
especially not in regard to different VEGF isoforms. We
demonstrated a significant decrease in VEGF165 isoform and
likely other VEGF isoforms 1 day after spinal cord contusion
with a sustained significant decrease in protein levels up to
1 month after injury. The preincubation assay confirmed that
the VEGF165 isoform was significantly decreased after injury.
Interestingly, a recent study also observed a significant de-
FIG. 5. Vascular endothelial growth factor (VEGF) immunolabeling of coronal sections from uninjured and injured spinal
cord. VEGF expression is observed in both gray and white matter regions in uninjured spinal cord (A). Astrocytes labeled
with glial fibrillary acidic protein (GFAP) also identify gray and white matter regions in uninjured tissue (B). A 56-day post-
injured spinal cord section showing VEGF labeling around the lesion cavity with a loss of defined gray and white matter
regions (C). Astrocytic labeling with GFAP indicates an increase around the lesion epicenter (D). Scale bar¼ 500 mm.
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crease in VEGF protein expression following ischemic SCI
(Savas et al., 2008). In that study, no attempt was made to
examine which particular VEGF protein isoforms were de-
creased. While previous SCI studies have demonstrated a
significant increase in the expression of VEGF mRNA and
VEGF receptors after injury (Choi et al., 2007; Skold et al.,
2000) to the best of our knowledge, VEGF protein levels fol-
lowing contusion SCI have not been quantified.
A number of contributing factors may play a role in the
observed decreases in VEGF protein level. We showed that
VEGFwas normally expressed in neurons and astrocytes (Fig.
4A,D). The dramatic loss of neurons at the site of injury 1 day
after SCI (Nesic-Taylor et al., 2005) may contribute to the
overall decrease in VEGF observed in this study. Ad-
ditionally, roughly 50% of astrocytes die 1 day after contusion
SCI at the epicenter of injury (Grossman et al., 2001). This may
imply that the loss of VEGF-expressing neurons and astro-
cytes contributes to decreased VEGF synthesis in acutely in-
jured spinal cords. While the initial loss of both astrocytic and
neuronal populations appears to result in the reduction of
VEGF protein levels, astrocytic replacement, and activation in
the chronic phase of injury (Grossmann et al., 2001) does not
seem to contribute to the restoration of VEGF levels. Possible
downregulation of VEGF levels by activated astrocytes in
chronically injured cords remains to be determined.
Although the loss of VEGF-expressing cells is likely to be
the main cause of decreased VEGF protein levels in injured
spinal cords, it may not be the only one. All our VEGF Wes-
tern blots at all time points analyzed (1 day to 1 month post-
SCI; n¼ 5 per time point; Figs. 1 and 3) showed a very strong
band (<10 kD) observed only in injured spinal cords that may
represent degraded VEGF. The VEGF immunolableing ob-
served in the injured spinal cord may be that of the degraded
VEGF (Fig. 5C). Previous studies have demonstrated that
proteolysis of VEGF is increased in chronic wounds and that
proteases such as plasmin are involved (Lauer et al., 2000).
Interestingly, when plasmin is injected into the brain, it results
in considerable edema from a possible effect on the endoge-
nous VEGF which in turn may have an effect on the blood-
brain barrier both acutely and chronically (Armao et al., 1997;
Figueroa et al., 1998; Xue and Del Bigio, 2001). Thus, SCI-
induced degradation of VEGFmay be a novelmechanism that
regulates protein levels and the effectiveness of VEGF in in-
jured spinal cord.
Neuroprotective effects of VEGF165
Significant decreases in the VEGF protein levels in injured
spinal cord may affect the various roles of VEGF in the CNS:
neurogenesis and angiogenesis that take place in the sec-
ondary and chronic phase after SCI and neuronal protection
that is impaired in the acute phase post-injury. In this report,
we focused on putative neuroprotective effects of VEGF and
possible consequences of SCI-induced reduction in VEGF on
neuronal survival. Studies on the effects of VEGF on neuro-
genesis and angiogenesis in SCI are underway.
Recent data from several groups indicate that one of the
important roles of VEGF in the CNS is in the regulation of
neuronal survival. For example, Jin et al. (2000) demonstrated
that the application of exogenous VEGF promotes survival of
rat cerebral neurons in culture and rescues HN33 hippocam-
pal cells from death by serum withdrawal. It has been re-
ported that VEGF also has neuroprotective effects in different
CNS injury models (Facchiano et al., 2002; Lambrechts et al.,
2003, 2004; Oosthuyse et al., 2001; Zachary, 2005). In these
studies, it was determined that the survivial effects of VEGF
are mediated through VEGFR2 triggering the anti-apoptotic
pathway involving the phospatidylinositol 3’-kinase (PI3K)–
dependent activation of the serine=threonine kinase, Akt, or
PKB (Zachary, 2005). Thus, we hypothesized that acute ex-
ogenous administration of VEGF165 would counteract SCI–
induced reduction in VEGF165 and affect neuronal survival
after SCI. Additionally, it has been previously shown that
spinal neurons express VEGF receptors (Choi et al., 2007); so,
exogenous administration of VEGF in acutely injured spinal
cords would predictably affect the survival of spinal neurons
by the activation of the PI3K=Akt pathway. Our results,
however, indicated that supplementing the injured environ-
ment with VEGF165 showed no significant effect in neuronal
survival. The lack of neuroprotection may seem intriguing
since recent reports demonstrated that transfection of neuro-
nal and astrocytes with plasmids expressing VEGF165 has a
beneficial effect on the motor recovery after SCI (Choi et al.,
2007). However, it can also mean that VEGF autocrine effect
may differ from paracrine VEGF effects in regulating neuro-
nal survival. VEGF exerting an autocrine effect on neuronal
survival has been shown in a previous study (Ogunshola et al.,
2000).
Our result also suggests that other VEGF isoformsmight be
more important for direct protection of neuronal survival
early on after SCI. For example, it has been shown that
VEGF121 may also have a neuroprotective role by binding to
VEGFR-2 and triggering PI3K=Akt pathway (Zachary, 2005).
As to which VEGF isoform in injured spinal cords is involved
in neuronal protection remains to be determined. Our result
shown in Figure 6 is consistent with VEGF isoforms other than
165, which is important for neuroprotection; however, sup-
pression of endogenous VEGF with a neutralizing antibody
(used in all our Western blots), which blocks the activity of all
FIG. 6. A neuroprotection study was performed on four
groups that received an acute epicenter injection of the fol-
lowing: vascular endothelial growth factor–165 (VEGF165),
anti-VEGF, or saline. Neuroprotection was assessed by
quantifying the number of neuronal nuclei (NeuNþ) cells 56
days post-injury. A significant decrease was observed in the
anti-VEGF-treated group (*) compared to VEGF165, saline,
and sham controls. No significant difference was observed in
the VEGF165-treated group. Error bars represent standard
error of the mean. Significance levels were set at p> 0.05.
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VEGF isoforms, resulted in greater reduction in neuronal
numbers after SCI compared to other groups. Similar to our
results, anti-VEGF when injected into the lateral ventricle of
rat brain after ischemia markedly increases infarct volume
(Bao et al., 1999).
Taken together, our results suggest that SCI induces de-
creases in different VEGF isoforms, and that one of those
isoforms is important for early neuronal protection after SCI.
It is unlikely that VEGF165, primarily involved in angiogenesis
and neurogenesis as reported previously, is the isoform in-
volved with neuroprotection. Therefore, the roles of other
VEGF isoforms in injured spinal cords and the one that has
direct neuroprotective effect remains to be determined. This
knowledge should help in designing more effective VEGF
treatments that would include several isoforms so that acti-
vated VEGF receptors on different cell types can exert their
full therapeutic potential.
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